Guardant Health (GH) announced that a jury in the U.S. District Court for the Northern District of California unanimously found in favor of Guardant Health on all of its claims
Guardant Health (GH) announced that a jury in the U.S. District Court for the Northern District of California unanimously found in favor of Guardant Health on all of its claims
Natera (NTRA) issued the following statement: “In 2021, Natera and Guardant Health (GH) filed false advertising cases against each other concerning statements both companies made more than three years ago
In a report released today, Tejas Savant from Morgan Stanley maintained a Buy rating on Guardant Health (GH – Research Report), with a price target of $42.00. The company’s shares
In a report released today, Sung Ji Nam from Scotiabank maintained a Buy rating on Guardant Health (GH – Research Report), with a price target of $47.00. The company’s shares
In a report released today, Daniel Arias from Stifel Nicolaus maintained a Buy rating on Guardant Health (GH – Research Report), with a price target of $45.00. The company’s shares